Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns

Table 3

Responses of various histological subtypes to anlotinib.

Histological subtype	CR; (%)	PR; (%)	SD; (%)	PD; (%)	ORR; (%)	DCR; (%)
FS	0 (0)	2 (22)	5 (56)	2 (22)	2 (22)	7 (78)
SS	0 (0)	1 (20)	3 (60)	1 (20)	1 (20)	4 (80)
UPS	0 (0)	0 (0)	2 (40)	3 (60)	0 (0)	2 (40)
LMS	0 (0)	1 (33)	0 (0)	2 (67)	1 (33)	1 (33)
LPS	0 (0)	0 (0)	2 (100)	0 (0)	0 (0)	2 (100)
CCS	0 (0)	1 (100)	0 (0)	0 (0)	1 (100)	1 (100)
ASPS	0 (0)	1 (100)	0 (0)	0 (0)	1 (100)	1 (100)
Others	0 (0)	0 (0)	4 (80)	1 (20)	0 (0)	4 (80)
Total	0 (0)	6 (19)	16 (52)	9 (29)	6 (19)	22 (71)